Home > Insider Trading > Charming Shoppes Inc

Charming Shoppes Inc (CHRS)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
21 - 30
Next >>

Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)

Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because...

Keep Reading →

June 14th, 2019 - Hedge Funds News

Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...

Keep Reading →

May 8th, 2019 - Hedge Funds News

Should You Buy Coherus Biosciences Inc (CHRS)?

Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter.

Keep Reading →

December 12th, 2018 - Hedge Funds News

13G Filing: Partner Fund Management and Coherus Biosciences Inc. (CHRS)

You can access the original SEC filing by clicking here.

Keep Reading →

July 6th, 2017 - Hedge Funds

Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback

Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional grant to the underwriters...

Keep Reading →

February 8th, 2017 - News Stock Analysis

Hedge Funds Are Betting On Coherus Biosciences Inc (CHRS)

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...

Keep Reading →

December 13th, 2016 - Hedge Funds News

AbbVie Inc (ABBV) Wins Patent Battle Against Coherus Biosciences Inc (CHRS)

The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has decided not to embark on the review of the 166 formulation patent of AbbVie Inc (NYSE:ABBV) as requested by Coherus ...

Keep Reading →

November 9th, 2016 - News

AbbVie Inc (ABBV) Stock: Skyrocketing On IP Chatter | Coherus Biosciences Inc (CHRS) Stock Tanking

AbbVie Inc (NYSE:ABBV) and Coherus Biosciences Inc (NASDAQ:CHRS) were both off to a relatively normal start in the market today. While both were trading in the green, they weren't gaining by much.

Keep Reading →

November 7th, 2016 - Market Movers News Stock Analysis

Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)

Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot of speculative attention ...

Keep Reading →

August 16th, 2016 - News Stock Analysis